Theriva Biologics Inc (TOVX)
1.28
0.00 (0.00%)
USD |
NYAM |
Nov 22, 16:00
1.29
+0.01
(+0.78%)
Pre-Market: 20:00
Theriva Biologics Free Cash Flow: -18.84M for Sept. 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
Date | Value |
---|---|
September 30, 2024 | -18.84M |
June 30, 2024 | -18.01M |
March 31, 2024 | -18.46M |
December 31, 2023 | -19.20M |
September 30, 2023 | -18.06M |
June 30, 2023 | -19.44M |
March 31, 2023 | -19.91M |
December 31, 2022 | -19.20M |
September 30, 2022 | -18.55M |
June 30, 2022 | -16.24M |
March 31, 2022 | -14.46M |
December 31, 2021 | -12.90M |
September 30, 2021 | -11.23M |
June 30, 2021 | -11.13M |
March 31, 2021 | -10.56M |
December 31, 2020 | -12.18M |
September 30, 2020 | -12.64M |
June 30, 2020 | -13.65M |
March 31, 2020 | -14.61M |
December 31, 2019 | -13.87M |
September 30, 2019 | -13.56M |
June 30, 2019 | -14.10M |
March 31, 2019 | -15.42M |
December 31, 2018 | -17.28M |
September 30, 2018 | -17.92M |
Date | Value |
---|---|
June 30, 2018 | -19.04M |
March 31, 2018 | -20.48M |
December 31, 2017 | -20.42M |
September 30, 2017 | -27.24M |
June 30, 2017 | -28.65M |
March 31, 2017 | -28.77M |
December 31, 2016 | -28.47M |
September 30, 2016 | -28.73M |
June 30, 2016 | -38.20M |
March 31, 2016 | -39.63M |
December 31, 2015 | -39.39M |
September 30, 2015 | -33.16M |
June 30, 2015 | -22.11M |
March 31, 2015 | -18.13M |
December 31, 2014 | -16.13M |
September 30, 2014 | -14.06M |
June 30, 2014 | -11.23M |
March 31, 2014 | -9.564M |
December 31, 2013 | -7.755M |
September 30, 2013 | -9.816M |
June 30, 2013 | -9.533M |
March 31, 2013 | -9.176M |
December 31, 2012 | -8.926M |
September 30, 2012 | -4.881M |
June 30, 2012 | -4.343M |
Free Cash Flow Range, Past 5 Years
-19.91M
Minimum
Mar 2023
-10.56M
Maximum
Mar 2021
-15.66M
Average
-15.42M
Median
Free Cash Flow Benchmarks
Merck & Co Inc | 14.84B |
Pro-Dex Inc | 6.406M |
BioCardia Inc | -7.309M |
NovaBay Pharmaceuticals Inc | -4.812M |
Palatin Technologies Inc | -32.57M |
Free Cash Flow Related Metrics
Cash from Operations (Quarterly) | -3.913M |
Cash from Financing (Quarterly) | 3.716M |
Free Cash Flow Per Share (Quarterly) | -3.449 |
Free Cash Flow Yield | -1.80K% |